

NFS-01 Neuroscience Frontier Symposium 01**En**

9月1日 (火) 16:00 ~ 17:30

第10会場 (岡山県医師会館 2F 三木記念ホール)

New approaches aimed for the development of disease modifying therapies of Alzheimer's disease and other dementia diseases

Chairs : Takeshi Iwatsubo

The University of Tokyo, Neuropathology

Kenjiro Ono

Division of Neurology, Department of Medicine, Showa University School of Medicine

NFS-01-1 The pathological link of glia activation with amyloid clearance in Alzheimer disease

Taisuke Tomita

Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan

NFS-01-2 Principles of Inflammasome Priming and Inhibition: Implications for Neurodegenerative Disorders

Giulio M. Pasinetti

Icahn School of Medicine at Mount Sinai, USA / James J Peters Veterans Affairs Medical Center, USA

NFS-01-3 HMW A β oligomers are important targets for disease modifying approach of Alzheimer's disease

Kenjiro Ono

Division of Neurology, Department of Medicine, School of Medicine, Showa University, Japan

NFS-01-4 発表キャンセル

Original discovery and therapy for SCA from Japan to the world

Chairs : Yoshitaka Nagai

Department of Neurotherapeutics, Osaka University Graduate School of Medicine

Kinya Ishikawa

The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University

NFS-02-1 Pathogenesis of spinocerebellar ataxia type 31 (SCA31)

Kinya Ishikawa

The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University, Japan

NFS-02-2 Current clinical characteristics of Asidan (SCA36)

Yasuyuki Ohta

Department of Neurology, Okayama University, Japan

NFS-02-3 Development of disease-modifying therapy for polyglutamine-linked SCA

Yoshitaka Nagai

Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Japan

NFS-02-4 Antisense oligonucleotide therapy in spinocerebellar ataxia type 3 (SCA3) / Machado-Joseph disease

Henry L. Paulson

University of Michigan, USA

NFS-03 Neuroscience Frontier Symposium 03

Leading edge of ALS research

Chairs : Clotilde Lagier-Tourenne

Massachusetts General Hospital / Harvard Medical School

Masahisa Katsuno

Department of Neurology, Nagoya University

NFS-03-1 Antibody-based Therapeutic strategies for ALS targeting misfolded proteins

Makoto Urushitani

Department of Neurology, Shiga University of Medical Science, Japan

NFS-03-2 Disruption of RNA metabolism in neurodegenerative diseases and emerging therapeutic strategies

Clotilde Lagier-Tourenne

Sean M. Healey & AMG Center for ALS at the Massachusetts General Hospital, USA / Harvard Medical School, USA

NFS-03-3 Glia-immune communication in ALS

Koji Yamanaka

Department of Neuroscience and Pathobiology, RIEM, Nagoya University, Japan

NFS-03-4 TDP-43 facilitates exocytosis: unexpected link between ALS and diabetes

Masahisa Katsuno

Department of Neurology, Nagoya University Graduate School of Medicine, Japan